6-(3-chlorophenylamino)-N-cyclohexylmethyl-4-isopropylnicotinamide | 676627-22-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(3-chlorophenylamino)-N-cyclohexylmethyl-4-isopropylnicotinamide
• 英文别名: 6-(3-chloroanilino)-N-(cyclohexylmethyl)-4-propan-2-ylpyridine-3-carboxamide
• CAS: 676627-22-8
• 化学式: C₂₂H₂₈ClN₃O
• 分子量: 385.937
• InChiKey: KGUMVSFHHKARSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  54
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6-chloro-N-cyclohexylmethyl-nicotinamide 以 四氢呋喃 为溶剂， 反应 16.08h， 生成 6-(3-chlorophenylamino)-N-cyclohexylmethyl-4-isopropylnicotinamide
  参考文献：
  名称：

  [EN] PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS
  [FR] DERIVES DE PYRIDINE MODULATEURS DU RECEPTEUR CB2

  摘要：

  本发明涉及新型吡啶衍生物，含有这些化合物的药物组合物以及它们在治疗疾病，特别是由大麻素受体活性增加或减少直接或间接引起的疾病中的应用。

  公开号：

  WO2004029026A1

文献信息

• [EN] COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE<br/>[FR] COMBINAISON DE MODULATEURS DU CB2 ET D'INHIBITEURS DE LA PDE4 UTILISEE EN MEDECINE
  申请人：GLAXO GROUP LTD

  公开号：WO2005074939A1

  公开（公告）日：2005-08-18

  Combination of one or more CB2 modulators such as a compound of formula (I), (II) and (III); and one more PDE4 inhibitors are useful of treating conditions which are mediated by the activity of CB2 receptors or conditions which are mediated by PDE4, such as an immune disorder, an inflamatory disorder, pain, rheumatoid.

  一种或多种CB2调节剂的组合，例如式(I)、(II)和(III)的化合物；以及一种或多种PDE4抑制剂对于治疗由CB2受体活性介导的疾病或由PDE4介导的疾病，如免疫紊乱、炎症性疾病、疼痛、类风湿等症状是有用的。
• Process for preparing encapsulated metalloporphyrin catalyst and process for oxidation of alcohols
  申请人：Naik H. Rajan

  公开号：US20060167313A1

  公开（公告）日：2006-07-27

  The present invention relates to a polystyrene encapsulated catalyst containing metalloporphyrin of formula I: wherein R 1 , R 2 , and R 3 are individually selected from the group consisting of alkyl, halo, nitro and amino groups and M is a metal atom selected from the group consisting of Fe, Co, Ni, Mn, Cu, Ru, Pt and Pd and to its use in oxidation of alcohols.

  本发明涉及一种聚苯乙烯包埋的配方I的金属卟啉催化剂，其中R1、R2和R3分别选自烷基、卤素、硝基和氨基等基团，M为选自Fe、Co、Ni、Mn、Cu、Ru、Pt和Pd的金属原子，并且涉及其在醇的氧化中的应用。
• [EN] USE OF METALLOPORPHYRINS AND SALEN COMPLEXES FOR THE CATALYTIC OXIDATION OF ORGANIC COMPOUNDS<br/>[FR] UTILISATION DE MÉTALLOPORPHYRINES ET DE COMPLEXES DE TYPE SALEN POUR L'OXYDATION CATALYTIQUE DE COMPOSÉS ORGANIQUES
  申请人：PHARMA THINQ

  公开号：WO2013123513A1

  公开（公告）日：2013-08-22

  A method of decomposing an organic substrate includes identifying an organic substrate or its constituents having one or more desired or undesired properties; and contacting the organic substrate with an oxidizing agent and a catalyst selected from the group consisting of sterically hindered and electronically activated metallotetraphenylporphyrms, metallophthalocyanines and metallosalen complexes in an aqueous or aqueous-organic solution to produce a treated composition comprising one or more degradation products, wherein the degradation products have one or more desired properties and/or lack the undesired properties of the organic substrate.

  一种分解有机底物的方法包括识别具有一个或多个期望或不期望性质的有机底物或其组分；并将有机底物与氧化剂和从甲苯基卟啉金属、金属酞菁和金属萨伦络合物中选择的催化剂接触在水性或水性-有机溶液中，以产生包含一个或多个降解产物的处理组合物，其中降解产物具有一个或多个期望性质和/或不具有有机底物的不期望性质。
• Pyridine derivatives as cb2 receptor modulators
  申请人：Eatherton John Andrew

  公开号：US20060240048A1

  公开（公告）日：2006-10-26

  The present invention relates to novel pyridine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

  本发明涉及新型的吡啶衍生物、含有这些化合物的药物组合物以及它们在治疗疾病，特别是由于大麻素受体活性增加或减少而直接或间接引起的疼痛等疾病中的应用。
• Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine
  申请人：Brown Andrew James

  公开号：US20080132505A1

  公开（公告）日：2008-06-05

  Combination of one or more CB2 modulators and one or more PDE4 inhibitors, and method of treating conditions which are mediated by the activity of CB2 receptors or conditions which are mediated by PDE4.

  一种由一种或多种CB2调节剂和一种或多种PDE4抑制剂组合而成的治疗方法，用于治疗由CB2受体活性介导的疾病或由PDE4介导的疾病。